Skip to Main Content

Author Details

Monique J Roobol
Erasmus MC Cancer Institute, University Medical Center Rotterdam
1988
444
71
PMIDPaper TitleJournal TitlePublished Year
37414703Clinical Characterization of Patients Diagnosed with Prostate Cancer and Undergoing Conservative Management: A PIONEER Analysis Based on Big Data.Eur Urol2024
37919190Prostate Cancer Mortality Among Elderly Men After Discontinuing Organised Screening: Long-term Results from the European Randomized Study of Screening for Prostate Cancer Rotterdam.Eur Urol2024
37607322Performance of magnetic resonance imaging-based prostate cancer risk calculators and decision strategies in two large European medical centres.BJU Int2024
34483041Interaction of MRI and active surveillance in prostate cancer: Time to re-evaluate the active surveillance inclusion criteria.Urol Oncol2023
37704541Early Detection of Prostate Cancer in the European Union: Combining Forces with PRAISE-U.Eur Urol2023
37945903Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants.Nat Genet2023
37690917From Screening to Mortality Reduction: An Overview of Empirical Data on the Patient Journey in European Randomized Study of Screening for Prostate Cancer Rotterdam After 21 Years of Follow-up and a Reflection on Quality of Life.Eur Urol Oncol2023
38046899Research protocol to identify progression and death amongst patients with metastatic hormone-sensitive prostate cancer treated with available treatments: PIONEER IMI's "big data for better outcomes" program.Int J Surg Protoc2023
37534902The combined role of MRI prostate and prostate health index in improving detection of significant prostate cancer in a screening population of Chinese men.Asian J Androl2023
35726641Circulating insulin-like growth factors and risks of overall, aggressive and early-onset prostate cancer: a collaborative analysis of 20 prospective studies and Mendelian randomization analysis.Int J Epidemiol2023
37292833Evaluating Approaches for Constructing Polygenic Risk Scores for Prostate Cancer in Men of African and European Ancestry.medRxiv2023
37088597Relationship Between Baseline Prostate-specific Antigen on Cancer Detection and Prostate Cancer Death: Long-term Follow-up from the European Randomized Study of Screening for Prostate Cancer.Eur Urol2023
37187725The Patient Journey from Randomization to Detection of Prostate Cancer and Death: Results from ERSPC Rotterdam.Eur Urol Open Sci2023
37311464Evaluating approaches for constructing polygenic risk scores for prostate cancer in men of African and European ancestry.Am J Hum Genet2023
37109015Active Surveillance for Prostate Cancer: Past, Current, and Future Trends.J Pers Med2023
37441346How to follow the new EU Council recommendation and improve prostate cancer early detection: the Prostaforum 2022 declaration.Eur Urol Open Sci2023
37305629A literature review to understand health literacy in men with prostate cancer on active surveillance.Transl Androl Urol2023
37268512The Europa Uomo Patient Reported Outcome Study 2.0-Prostate Cancer Patient-reported Outcomes to Support Treatment Decision-making.Eur Urol Focus2023
37032279Urinary Incontinence and Sexual Function After the Introduction of NeuroSAFE in Radical Prostatectomy for Prostate Cancer.Eur Urol Focus2023
37029074A Detailed Evaluation of the Effect of Prostate-specific Antigen-based Screening on Morbidity and Mortality of Prostate Cancer: 21-year Follow-up Results of the Rotterdam Section of the European Randomised Study of Screening for Prostate Cancer.Eur Urol2023
36408660Shifting risk-stratified early prostate cancer detection to a primary healthcare setting.BJU Int2023
36519924Sexual and urinary function in prostate cancer clinical studies and the Europa Uomo Patient Reported Outcome Study: does it match?Minerva Urol Nephrol2023
36915892Prostate cancer risk assessment by the primary care physician and urologist: transabdominal- versus transrectal ultrasound prostate volume-based use of the Rotterdam Prostate Cancer Risk Calculator.Transl Androl Urol2023
36710133Best Current Practice and Research Priorities in Active Surveillance for Prostate Cancer-A Report of a Movember International Consensus Meeting.Eur Urol Oncol2023
36639296Mapping European Association of Urology Guideline Practice Across Europe: An Audit of Androgen Deprivation Therapy Use Before Prostate Cancer Surgery in 6598 Cases in 187 Hospitals Across 31 European Countries.Eur Urol2023
36631536The transition from transrectal to transperineal prostate biopsy without antibiotic prophylaxis: Cancer detection rates and complication rates.Prostate Cancer Prostatic Dis2023
36245015External validation of the Rotterdam prostate cancer risk calculator within a high-risk Dutch clinical cohort.World J Urol2023
34453109Initial Prostate Health Index (phi) and phi density predicts future risk of clinically significant prostate cancer in men with initial negative prostate biopsy: a 6-year follow-up study.Prostate Cancer Prostatic Dis2022
35384019Large and small cribriform architecture have similar adverse clinical outcome on prostate cancer biopsies.Histopathology2022
35803346Predictive Value of Cribriform and Intraductal Carcinoma for the Nomogram-based Selection of Prostate Cancer Patients for Pelvic Lymph Node Dissection.Urology2022
35379637Diagnostic and prognostic factors in patients with prostate cancer: a systematic review.BMJ Open2022
35437217A Multivariable Approach Using Magnetic Resonance Imaging to Avoid a Protocol-based Prostate Biopsy in Men on Active Surveillance for Prostate Cancer-Data from the International Multicenter Prospective PRIAS Study.Eur Urol Oncol2022
35536200NeuroSAFE in radical prostatectomy increases the rate of nerve-sparing surgery without affecting oncological outcome.BJU Int2022
35464652Development of a prediction model in female pure or predominant urge urinary incontinence: a retrospective cohort study.Ther Adv Urol2022
35629173Secondary Treatment for Men with Localized Prostate Cancer: A Pooled Analysis of PRIAS and ERSPC-Rotterdam Data within the PIONEER Data Platform.J Pers Med2022
35850672Cross-cultural differences in men on active surveillance' anxiety: a longitudinal comparison between Italian and Dutch patients from the Prostate cancer Research International Active Surveillance study.BMC Urol2022
35911085Detailed Evaluation of Androgen Deprivation Overtreatment in Prostate Cancer Patients Compared to the European Association of Urology Guidelines Using Long-term Data from the European Randomised Study of Screening for Prostate Cancer Rotterdam.Eur Urol Open Sci2022
36381164Active surveillance for low-risk prostate cancer: well established, yet avoided?Cent European J Urol2022
35950035Reducing prostate biopsies and magnetic resonance imaging with prostate cancer risk stratification.BJUI Compass2022
35974245Serum PSA-based early detection of prostate cancer in Europe and globally: past, present and future.Nat Rev Urol2022
35184906Updating and Integrating Core Outcome Sets for Localised, Locally Advanced, Metastatic, and Nonmetastatic Castration-resistant Prostate Cancer: An Update from the PIONEER Consortium.Eur Urol2022
35146793Shared decision making of burdensome surveillance tests using personalized schedules and their burden and benefit.Stat Med2022
34993496Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment.HGG Adv2022
35024633Prostate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of Needing Treatment: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium.Eur Urol Open Sci2022
34706119Cribriform architecture outperforms Gleason pattern 4 percentage and tertiary Gleason pattern 5 in predicting the outcome of Grade Group 2 prostate cancer patients.Histopathology2022
34702647Improving Guideline Adherence in Urology.Eur Urol Focus2022
34717190Improving the prediction of biochemical recurrence after radical prostatectomy with the addition of detailed pathology of the positive surgical margin and cribriform growth.Ann Diagn Pathol2022
31431394Assessing a patient's individual risk of biopsy-detectable prostate cancer: Be aware of case mix heterogeneity and a priori likelihood.Eur Urol Oncol2021
33493004Reply by Authors.J Urol2021
33623038Polygenic hazard score is associated with prostate cancer in multi-ethnic populations.Nat Commun2021
  • 1 - 50 of 444

Recommended Authors

Giovanni Motterle
Mayo Clinic
Career Start Year 2017
Number of shared co-authors 7
Robert T Dess
University of Michigan ann arbor
Career Start Year 2016
Number of shared co-authors 12
Travis Gerke
The Prostate Cancer Clinical Trials Consortium
Career Start Year 2014
Number of shared co-authors 20
Neil Mendhiratta
National Cancer Institute, National Institutes of Health
Career Start Year 2013
Number of shared co-authors 1
Adam B Weiner
Northwestern University Feinberg School of Medicine
Career Start Year 2013
Number of shared co-authors 6
Simpa S Salami
University of Michigan Medical School ann arbor
Career Start Year 2012
Number of shared co-authors 13
Devin N Patel
university of california san diego School of Medicine
Career Start Year 2011
Number of shared co-authors 2
Daniel E Spratt
University Hospitals Seidman Cancer Center, Case Western Reserve University
Career Start Year 2010
Number of shared co-authors 30
Michael A Liss
University of Texas Health San Antonio
Career Start Year 2008
Number of shared co-authors 13
Jeffrey J Tosoian
Vanderbilt University Medical Center
Career Start Year 2008
Number of shared co-authors 13
Alastair D Lamb
University of Oxford
Career Start Year 2007
Number of shared co-authors 20
Jonathan L Wright
University of Washington Medical Center
Career Start Year 2005
Number of shared co-authors 18
Channing J Paller
Johns Hopkins University School of Medicine
Career Start Year 2004
Number of shared co-authors 7
Alejandro Berlin
University of Toronto, Princess Margaret Cancer Centre
Career Start Year 2004
Number of shared co-authors 33
Thorsten Schlomm
Charite - University Hospital Berlin
Career Start Year 2004
Number of shared co-authors 18
Ashley E Ross
Northwestern University
Career Start Year 2003
Number of shared co-authors 18
Tim Dudderidge
University Hospital Southampton NHS Foundation Trust
Career Start Year 2002
Number of shared co-authors 36
John K Parsons
university of california san diego Moores Cancer Center
Career Start Year 2001
Number of shared co-authors 35
Robert Jeffrey Karnes
Mayo Clinic
Career Start Year 2000
Number of shared co-authors 32
Girish S Kulkarni
Princess Margaret Cancer Centre, University Health Network, University of Toronto
Career Start Year 1999
Number of shared co-authors 10
Mark K Buyyounouski
Stanford University
Career Start Year 1999
Number of shared co-authors 5
Lars Egevad
Karolinska Institute
Career Start Year 1995
Number of shared co-authors 19
Robert E Reiter
David Geffen School of Medicine at university of california los angeles
Career Start Year 1993
Number of shared co-authors 25
Byung Ha Chung
Yonsei University College of Medicine and Gangnam Severance Hospital
Career Start Year 1992
Number of shared co-authors 10
Fred Saad
University of Montreal Health Center
Career Start Year 1990
Number of shared co-authors 33
Paul L Nguyen
Brigham and Women's Hospital and Dana Farber Cancer Institute, Harvard Medical School
Career Start Year 1990
Number of shared co-authors 33
Anthony V D'Amico
Duke University Medical Center
Career Start Year 1988
Number of shared co-authors 31
Armen Aprikian
McGill University Health Centre, McGill University
Career Start Year 1987
Number of shared co-authors 19
Alan W Partin
The Brady Urological Institute, Johns Hopkins University School of Medicine
Career Start Year 1987
Number of shared co-authors 57
Philip W Kantoff
Memorial Sloan Kettering Cancer Center
Career Start Year 1981
Number of shared co-authors 49

Collaborators

Theodorus H van der Kwast
University Health Network, University of Toronto
Co-authored papers 65
Geert J L H van Leenders
Erasmus MC Cancer Institute, University Medical Center
Co-authored papers 54
Ewout W Steyerberg
Leiden University Medical Center
Co-authored papers 51
Sebastiaan Remmers
Erasmus MC Cancer Institute, University Medical Center Rotterdam
Co-authored papers 47
Roderick C N van den Bergh
St. Antonius Hospital
Co-authored papers 33
Maciej Kwiatkowski
University of Basel, Academic Hospital Braunschweig
Co-authored papers 24
David E Neal
University of Oxford, John Radcliffe Hospital
Co-authored papers 21
Demetrius Albanes
Co-authored papers 16
Ruth C Travis
Co-authored papers 16
Janet L Stanford
Fred Hutchinson Cancer Research Center
Co-authored papers 15
Lorelei A Mucci
Co-authored papers 15
Freddie C Hamdy
University of Oxford
Co-authored papers 15
Henrik Gr??nberg
Karolinska Institute
Co-authored papers 15
Kathryn L Penney
Co-authored papers 15
Cezary Cybulski
International Hereditary Cancer Center, Pomeranian Medical University
Co-authored papers 14
Fredrik Wiklund
Co-authored papers 14
Sonja I Berndt
Co-authored papers 14
Sue A Ingles
Co-authored papers 14
Catharine M L West
University of Manchester
Co-authored papers 14
Johanna Schleutker
Institute of Biomedicine, University of Turku
Co-authored papers 14
Børge G Nordestgaard
Co-authored papers 14
Christopher A Haiman
University of Southern California
Co-authored papers 14
Zsofia Kote-Jarai
The Institute of Cancer Research
Co-authored papers 14
Esther I Verhoef
Erasmus University Medical Center
Co-authored papers 13
Douglas F Easton
University of Cambridge
Co-authored papers 13
Charlotte F Kweldam
Anser Prostate Operation Clinic, Maasstad Hospital
Co-authored papers 13
Guido Jenster
Erasmus University Medical Center
Co-authored papers 13
Mieke Van Hemelrijck
School of Cancer and Pharmaceutical Sciences, King's College London
Co-authored papers 12
Kay-Tee Khaw
Co-authored papers 12
Esther M John
Co-authored papers 12
Release 1.2